Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Genor Biopharma Holdings  / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/jhbp-cy-holdings-ltd" target="_blank" data-smartkarma-citation="entities:29201:1" rel="noopener">JHBP (Genor) (6998 HK)</a> received approval in China for its first commercial drug, GB242, a biosimilar to Remicade (infliximab). Approved indications have an addressable patient population of 10 million.</li>
<li>The company is also expected to obtain marketing approval for its drug candidate for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL) in China this year.</li>
<li>In-Licensed GB491 (lerociclib) has entered in two phase 3 clinical trials for first and second-line treatments of breast cancer. NDA for GB491 is expected to be filed in 2023.</li>
</ul>



JHBP (Genor) (6998 HK) received approval in China for its first commercial drug, GB242, a biosimilar to Remicade (infliximab). Approved indications have an addressable patient population of 10 million.
The company is also expected to obtain marketing approval for its drug candidate for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL) in China this year.
In-Licensed GB491 (lerociclib) has entered in two phase 3 clinical trials for first and second-line treatments of breast cancer. NDA for GB491 is expected to be filed in 2023.


Genor Biopharma (6998 HK): First Product Approved in China; Late-Stage Pipeline Entails Visibility

Independent Research, SPACs, SPAC Track

SPAC Track

Independent Research, SPACs

Equity Capital Markets

<ul><li>Vickers Vantage Corp. I (VCKA) &amp; Scilex Holding Company (a subsidiary of Sorrento Therapeutics) (Valuation: $440M EV)</li><li>Pono Capital Corp (PONO) &amp; Benuvia (Valuation: $440M EV)</li><li>Brookline Capital Acquisition Corp. (BCAC) &amp; Apexigen (Valuation: $205M pre-money equity)</li></ul>

Vickers Vantage Corp. I (VCKA) &amp; Scilex Holding Company (a subsidiary of Sorrento Therapeutics) (Valuation: $440M EV)Pono Capital Corp (PONO) &amp; Benuvia (Valuation: $440M EV)Brookline Capital Acquisition Corp. (BCAC) &amp; Apexigen (Valuation: $205M pre-money equity)

<ul><li>Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (VCKA) Enter into Letter of Intent for Proposed Business Combination</li><li>US regulators probe Trump social media SPAC deal, seeking information on trading before the deal was announced as well as dealings between the two group</li><li>Lucid Group Inc. (LCID) disclosed it’s become the latest electric-vehicle maker to come under U.S. investigation following a merger with a blank-check company</li></ul>

Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (VCKA) Enter into Letter of Intent for Proposed Business CombinationUS regulators probe Trump social media SPAC deal, seeking information on trading before the deal was announced as well as dealings between the two groupLucid Group Inc. (LCID) disclosed it’s become the latest electric-vehicle maker to come under U.S. investigation following a merger with a blank-check company

United States

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic, and infectious diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sorrento Therapeutics (SRNE US)

Genor Biopharma (6998 HK): First Product Approved in China; Late-Stage Pipeline Entails Visibility

Genor obtained marketing approval for its first product in China, one more is expected this year. Commercial execution remains the key near-term...

Tina Banerjee

The SPAC Week in Review

Vickers Vantage Corp. I (VCKA) & Scilex Holding Company (a subsidiary of Sorrento Therapeutics) (Valuation: $440M EV). Pono Capital Corp (PONO) &...

SPAC Track

The Nightcap from SPAC Track

Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (VCKA) Enter into Letter of Intent for Proposed...

SPAC Track

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)